We are Vivodyne.

Dr. Georgescu spearheads Vivodyne’s vision of reshaping therapeutics development. The loss of translation between animal studies and human trials compelled him to co-found Vivodyne in 2020 and create an entirely new platform from the ground up. With a Ph.D. from Dr. Huh’s esteemed organ-chip research group at the University of Pennsylvania, his expertise lies in human-tissue engineering, robotics, and machine learning. His prior achievements include sending lab-grown tissues with NASA to space and developing DNA synthesis chips that remain industry staples to this day.

Lorem ipsum dolor sit amet consectetur. Ultrices dignissim vulputate egestas quis arcu sit pulvinar. Est hendrerit sem integer sit massa ipsum justo vitae. Lorem sit ac scelerisque sagittis mollis ut. Etiam porta ac blandit pellentesque neque nibh. Egestas est sapien parturient quis. Vitae nisi et consequat vestibulum tincidunt. Adipiscing sapien ridiculus ultrices eu aliquam nibh aliquam elementum consequat. Eget feugiat lobortis id enim pellentesque sapien ut mauris a. Nunc id gravida quis facilisis eu proin. Mauris sed amet tincidunt mauris sit odio. Amet enim dui et turpis fermentum mattis eget venenatis. Id odio morbi cursus facilisi quam nibh egestas vel porta.

Dr. Bahinski’s career spans academic research and large pharma, with more than 25 years of experience in the pharmaceutical industry. He served on the Advanced Technology Team at Harvard’s Wyss Institute, leading DARPA, and FDA collaborative efforts in development of organ chip systems. He has also served on several advisory boards and is currently member of the Science Board of the US FDA and formerly of the US EPA Board of Scientific Counselors. He is a member of the Editorial Board of the journal Applied In Vitro Toxicology. Dr. Bahinski is author/co-author of over 45 publications including peer-reviewed articles and book chapters.

Dr. Susan Billings is an accomplished commercial leader and stands at the forefront of the global life science sector, steering Vivodyne through the complex landscape of client relationships, technology innovation, and commercial strategy. Her extensive professional background includes a notable 11-year tenure at Curia, where she served as Vice President & Global Head of Business Development and led global business development teams to drive rapid growth with partnerships across the company’s diverse services. She earned her doctorate from UC Irvine in organic chemistry, and has prior experiences advancing through technical and operational roles at an oncology start-up and Merck.

Dr. Ivana Mikic leads the team behind Viovodyne’s AI platform with a focus on developing machine learning tools and cloud-based infrastructure to solve big data problems in drug discovery. Previously, Dr Mikić has led AI and software teams that developed highly successful solutions for digital pathology, high-content screening and computer vision tools for biomedical applications, resulting in two successful acquisitions. Former Ramón y Cajal Professor of computer vision at Universidad Autónoma de Madrid, Dr Mikić holds a PhD in Electrical and Computer Engineering from UC San Diego.